

Status: Currently Official on 16-Feb-2025
Official Date: Official as of 01-Sep-2022
Document Type: USP Monographs
DocId: GUID-9FFC920D-DB4E-4234-BE66-EEA42CABE9A8_2_en-US
DOI: https://doi.org/10.31003/USPNF_M70170_02_01
DOI Ref: o4p5x

© 2025 USPC
Do not distribute

Promethazine Hydrochloride Tablets

DEFINITION

Promethazine Hydrochloride Tablets contain NLT 95.0% and NMT 110.0% of the labeled amount of promethazine hydrochloride ($C_{17}H_{20}N_2S \cdot HCl$).

[NOTE—Throughout the following procedures, protect the samples, the Reference Standards, and the solutions containing them, by conducting the procedures without delay under subdued light or using low-actinic glassware.]

IDENTIFICATION

• A.

Standard solution: In a separator, dissolve 50 mg of [USP Promethazine Hydrochloride RS](#) in 40 mL of dilute hydrochloric acid (1 in 1000).

Sample solution: Shake a quantity of powdered Tablets, equivalent to 50 mg of promethazine hydrochloride, with 30 mL of chloroform, and filter into a beaker. Evaporate the chloroform, dissolve the residue in 40 mL of dilute hydrochloric acid (1 in 1000), and transfer the liquid to a separator.

Analysis: Separately treat the *Sample solution* and the *Standard solution* as follows. Add 2 mL of [1 N sodium hydroxide](#) and 15 mL of carbon disulfide to the separators, and shake for 2 min. Centrifuge if necessary to clarify the lower phase, and pass through a dry filter, collecting the filtrate from each separator in a small flask provided with a glass stopper. Reduce the volume of the carbon disulfide extracts to 4–5 mL, and proceed as directed in [Identification—Organic Nitrogenous Bases \(181\)](#), beginning with “Determine the absorption spectra”.

Acceptance criteria: Meet the requirements

• B. The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.

ASSAY

• PROCEDURE

Diluent: Dissolve 8.2 mL of [hydrochloric acid](#) in 1000 mL of water.

Mobile phase: Acetonitrile, water, and [triethylamine](#) (850:270:1)

System suitability stock solution: 1.2 mg/mL of [USP Promethazine Related Compound B RS](#) in *Diluent*. Sonicate to dissolve.

Standard solution: 0.1 mg/mL of [USP Promethazine Hydrochloride RS](#) in *Diluent*. Sonicate to dissolve.

System suitability solution: 0.09 mg/mL of [USP Promethazine Hydrochloride RS](#) and 0.12 mg/mL of [USP Promethazine Related Compound B RS](#) in *Diluent* from the *Standard solution* and *System suitability stock solution*, respectively

Sample stock solution: Nominally 2.5–5.0 mg/mL of promethazine hydrochloride prepared as follows. Transfer 20 Tablets to a volumetric flask of an appropriate size and add 50% of the flask volume of *Diluent*. Sonicate with swirling for NLT 20 min, or until the Tablets have fully disintegrated. Shake the flask for NLT 15 min and dilute with *Diluent* to volume.

Sample solution: Nominally 0.1 mg/mL of promethazine hydrochloride in *Diluent* from the *Sample stock solution*. Pass a portion through a filter of 0.45-μm pore size and use the clear filtrate.

Chromatographic system

(See [Chromatography \(621\)](#), [System Suitability](#).)

Mode: LC

Detector: UV 254 nm

Column: 3.9-mm × 30-cm; 10-μm packing L1

Flow rate: 2.5 mL/min

Injection volume: 20 μL

Run time: NLT 2.5 times the retention time of promethazine

System suitability

Samples: *System suitability solution* and *Standard solution*

[NOTE—The relative retention times for promethazine related compound B and promethazine are 0.82 and 1.0, respectively.]

Suitability requirements

Resolution: NLT 1.5 between promethazine and promethazine related compound B, *System suitability solution*

Tailing factor: NMT 1.5, *Standard solution*

Relative standard deviation: NMT 2.0%, *Standard solution*

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of promethazine hydrochloride ($C_{17}H_{20}N_2S \cdot HCl$) in the portion of Tablets taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak response from the *Sample solution*

r_S = peak response from the *Standard solution*

C_S = concentration of [USP Promethazine Hydrochloride RS](#) in the *Standard solution* (mg/mL)

C_U = nominal concentration of promethazine hydrochloride in the *Sample solution* (mg/mL)

Acceptance criteria: 95.0%–110.0%

PERFORMANCE TESTS

• [DISSOLUTION \(711\)](#)

Test 1

Medium: 0.01 N hydrochloric acid; 900 mL

Apparatus 1: 100 rpm

Time: 45 min

Standard solution: Prepare a solution with a known concentration of [USP Promethazine Hydrochloride RS](#) in *Medium*.

Sample solution: A filtered portion of the solution under test, suitably diluted with *Medium*

Instrumental conditions

Mode: UV

Analytical wavelength: Absorption maximum at about 249 nm

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of promethazine hydrochloride ($C_{17}H_{20}N_2S \cdot HCl$) dissolved:

$$\text{Result} = (A_U/A_S) \times (C_S/C_U) \times D \times 100$$

A_U = absorbance of the *Sample solution*

A_S = absorbance of the *Standard solution*

C_S = concentration of [USP Promethazine Hydrochloride RS](#) in the *Standard solution* (mg/mL)

C_U = nominal concentration of promethazine hydrochloride in the *Sample solution* (mg/mL)

D = dilution factor for the *Sample solution*

Tolerances: NLT 75% (Q) of the labeled amount of promethazine hydrochloride ($C_{17}H_{20}N_2S \cdot HCl$) is dissolved.

Test 2: If the product complies with this test, the labeling indicates that the product meets USP *Dissolution Test 2*.

Medium: 0.01 N hydrochloric acid; 900 mL

Apparatus 1: 100 rpm

Time: 15 min

Standard solution: ($L/900$) mg/mL of [USP Promethazine Hydrochloride RS](#) in *Medium*, where L is the label claim (mg/Tablet)

Sample solution: Pass a portion of the solution under test through a suitable filter of 0.45- μ m pore size.

Instrumental conditions

Mode: UV

Analytical wavelength: Absorption maximum at about 249 nm

Cell: 0.2 cm

Blank: *Medium*

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of promethazine hydrochloride ($C_{17}H_{20}N_2S \cdot HCl$) dissolved:

$$\text{Result} = (A_U/A_S) \times C_S \times V \times (1/L) \times 100$$

A_U = absorbance of the *Sample solution*

A_S = absorbance of the *Standard solution*

C_S = concentration of [USP Promethazine Hydrochloride RS](#) in the *Standard solution* (mg/mL)

V = volume of *Medium*, 900 mL

L = label claim (mg/Tablet)

Tolerances: NLT 80% (Q) of the labeled amount of promethazine hydrochloride ($C_{17}H_{20}N_2S \cdot HCl$) is dissolved.

- **UNIFORMITY OF DOSAGE UNITS** (905): Meet the requirements

IMPURITIES

Change to read:

• ORGANIC IMPURITIES

Diluent: Methanol and [triethylamine](#) (999:1)

Buffer: 3.7 g/L of [ammonium acetate](#) in water

Solution A: Buffer and acetonitrile (700:300)

Solution B: Acetonitrile

Mobile phase: See [Table 1](#).

Table 1

| Time (min) | Solution A (%) | Solution B (%) |
|------------|----------------|----------------|
| 0 | 100 | 0 |
| 10 | 60 | 40 |
| 18 | 60 | 40 |
| 18.1 | 100 | 0 |
| 25 | 100 | 0 |

System suitability stock solution: 0.5 mg/mL of [USP Promethazine Related Compound B RS](#) in *Diluent*

Standard stock solution: 0.5 mg/mL of [USP Promethazine Hydrochloride RS](#) in *Diluent*

System suitability solution: 5 µg/mL each of [USP Promethazine Hydrochloride RS](#) and [USP Promethazine Related Compound B RS](#) from the *Standard stock solution* and *System suitability stock solution*, respectively▲, in *Diluent*▲ (ERR 1-Sep-2022)

Standard solution: 5 µg/mL of [USP Promethazine Hydrochloride RS](#) from the *Standard stock solution*▲ in *Diluent*▲ (ERR 1-Sep-2022)

Sensitivity solution: 0.25 µg/mL of [USP Promethazine Hydrochloride RS](#) from the *Standard solution*▲ in *Diluent*▲ (ERR 1-Sep-2022)

Sample solution: Nominally 0.5 mg/mL of promethazine hydrochloride from powdered Tablets (NLT 20) prepared as follows. Transfer a quantity of powdered Tablets, equivalent to 50 mg of promethazine hydrochloride, to a volumetric flask of appropriate size and add 75% of the flask volume of *Diluent*. Shake the flask for NLT 5 min and dilute with *Diluent* to volume. Pass a portion through a suitable filter.

Chromatographic system

(See [Chromatography \(621\)](#), [System Suitability](#).)

Mode: LC

Detector: UV 234 and 249 nm

Column: 4.6-mm × 15-cm; 5-µm packing L1

Column temperature: 30°

Flow rate: 1.4 mL/min

Injection volume: 15 µL

System suitability**Samples:** *System suitability solution, Standard solution, and Sensitivity solution*[NOTE—See [Table 2](#) for the relative retention times.]**Suitability requirements****Resolution:** NLT 5.0 between promethazine and promethazine related compound B, *System suitability solution***Relative standard deviation:** NMT 3.0% at 234 and 249 nm, *Standard solution***Signal-to-noise ratio:** NLT 10 at 234 and 249 nm, *Sensitivity solution***Analysis****Samples:** *Standard solution and Sample solution*

Calculate the percentage of promethazine sulfoxide in the portion of Tablets taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times (1/F) \times 100$$

 r_U = peak response of promethazine sulfoxide at 234 nm from the *Sample solution* r_S = peak response of promethazine hydrochloride at 234 nm from the *Standard solution* C_S = concentration of [USP Promethazine Hydrochloride RS](#) in the *Standard solution* (mg/mL) C_U = nominal concentration of promethazine hydrochloride in the *Sample solution* (mg/mL) F = relative response factor (see [Table 2](#))

Calculate the percentage of all other degradation products in the portion of Tablets taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times (1/F) \times 100$$

 r_U = peak response of each degradation product at 249 nm from the *Sample solution* r_S = peak response of promethazine hydrochloride at 249 nm from the *Standard solution* C_S = concentration of [USP Promethazine Hydrochloride RS](#) in the *Standard solution* (mg/mL) C_U = nominal concentration of promethazine hydrochloride in the *Sample solution* (mg/mL) F = relative response factor (see [Table 2](#))**Acceptance criteria:** See [Table 2](#). Disregard peaks that are less than 0.05%.**Table 2**

| Name | Relative Retention Time | Relative Response Factor | Acceptance Criteria, NMT (%) |
|--|-------------------------|--------------------------|------------------------------|
| Promethazine sulfoxide ^a | 0.28 | 2.1 | 0.5 |
| Desmethyl promethazine ^b | 0.71 | 1.0 | 0.5 |
| Promethazine | 1.0 | — | — |
| Promethazine related compound B ^c | 1.3 | — | — |
| Phenothiazine | 1.7 | 2.0 | 0.5 |

| Name | Relative Retention Time | Relative Response Factor | Acceptance Criteria, NMT (%) |
|--|-------------------------|--------------------------|------------------------------|
| Any individual unspecified degradation product | — | 1.0 | 0.2 |
| Total degradation products | — | — | 1.0 |

^a *N,N*-Dimethyl-1-(10*H*-phenothiazin-10-yl)propan-2-amine sulfoxide.

^b *N*-Methyl-1-(10*H*-phenothiazin-10-yl)propan-2-amine.

^c This is a process impurity and is included for identification only. It is not to be reported and not to be included in the total degradation products.

ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve in tight, light-resistant containers. Store at controlled room temperature.
- **LABELING:** When more than one *Dissolution* test is given, the labeling states the test used only if *Test 1* is not used.
- **USP REFERENCE STANDARDS (11).**

[USP Promethazine Hydrochloride RS](#)

[USP Promethazine Related Compound B RS](#)

Isopromethazine hydrochloride;

N,N-Dimethyl-2-(10*H*-phenothiazin-10-yl)propan-1-amine hydrochloride.

$C_{17}H_{20}N_2S \cdot HCl$ 320.88

Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

| Topic/Question | Contact | Expert Committee |
|------------------------------------|---|---------------------------|
| PROMETHAZINE HYDROCHLORIDE TABLETS | Documentary Standards Support | SM52020 Small Molecules 5 |
| REFERENCE STANDARD SUPPORT | RS Technical Services RSTECH@usp.org | SM52020 Small Molecules 5 |

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. PF 41(4)

Current DocID: GUID-9FFC920D-DB4E-4234-BE66-EEA42CABE9A8_2_en-US

DOI: https://doi.org/10.31003/USPNF_M70170_02_01

DOI ref: [o4p5x](#)